IDT Australia Ltd (IDT)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:IDT Australia Ltd (IDT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013550
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
IDT Australia Ltd (IDT) is a contract manufacturing company that specializes in the development, scale-up and production of active pharmaceutical ingredients (APIs), microbiological and analytical testing, clinical trial research services and pharmacy services. The company also specializes in the post-discovery pharmaceutical life cycle. It manages Cytotoxic API’s, high potency API’s, anti-cancer drugs, antibiotics, anti-psychotics, beta lactams and controlled drugs. IDT provides a wide range of services, which can be customized to meet the specific requirements of its customer. The company also provides specialist clinical trial labeling, packaging and dispensing services. IDT is headquartered in Boronia, Victoria, Australia.

IDT Australia Ltd (IDT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
IDT Australia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
IDT Australia Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
IDT Australia Acquires Generic Drugs from Global Generics Company for USD14.8 Million 10
IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 11
Partnerships 12
Mayne Pharma Enters into Distribution Agreement with IDT Australia 12
ANI Pharma Enters into Agreement with IDT Australia 13
Equity Offering 14
WellSpring Pharma Services Invests USD3 Million in IDT Australia 14
IDT Australia Completes Private Placement Of Shares For US$2.8 Million 15
IDT Australia Completes Private Placement Of Shares For US$0.8 Million 16
IDT Australia Completes Rights Offering Of Shares For US$1.8 Million 17
Asset Transactions 18
I’rom Group Completes Acquisition of CMAX Clinical Trial Business from IDT Australia 18
Acquisition 19
I’rom Group to Acquire 61% Stake in CMAX from IDT Australia for USD7.6 Million 19
I’rom Completes Acquisition Of 18.8% Stake In IDT Australia For US$2 Million 20
IDT Australia Ltd – Key Competitors 21
IDT Australia Ltd – Key Employees 22
IDT Australia Ltd – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Strategy And Business Planning 24
Mar 30, 2016: IDT Greatly Expands Generics Production Capacity with New Manufacturing Partner 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
IDT Australia Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
IDT Australia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
IDT Australia Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
IDT Australia Acquires Generic Drugs from Global Generics Company for USD14.8 Million 10
IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 11
Mayne Pharma Enters into Distribution Agreement with IDT Australia 12
ANI Pharma Enters into Agreement with IDT Australia 13
WellSpring Pharma Services Invests USD3 Million in IDT Australia 14
IDT Australia Completes Private Placement Of Shares For US$2.8 Million 15
IDT Australia Completes Private Placement Of Shares For US$0.8 Million 16
IDT Australia Completes Rights Offering Of Shares For US$1.8 Million 17
I'rom Group Completes Acquisition of CMAX Clinical Trial Business from IDT Australia 18
I’rom Group to Acquire 61% Stake in CMAX from IDT Australia for USD7.6 Million 19
I'rom Completes Acquisition Of 18.8% Stake In IDT Australia For US$2 Million 20
IDT Australia Ltd, Key Competitors 21
IDT Australia Ltd, Key Employees 22

★海外企業調査レポート[IDT Australia Ltd (IDT)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Adama Ltd (000553):企業の財務・戦略的SWOT分析
    Adama Ltd (000553) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Vietnam Bank for Agriculture and Rural Development:企業の戦略的SWOT分析
    Vietnam Bank for Agriculture and Rural Development - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key compet …
  • DairiConcepts, L.P:企業の戦略・SWOT・財務情報
    DairiConcepts, L.P - Strategy, SWOT and Corporate Finance Report Summary DairiConcepts, L.P - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • ADMA Biologics Inc (ADMA):企業の財務・戦略的SWOT分析
    ADMA Biologics Inc (ADMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Oxford Biodynamics Plc:医療機器:M&Aディール及び事業提携情報
    Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neu …
  • Duke Energy Corporation:企業の戦略・SWOT・財務情報
    Duke Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Duke Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Gigasolar Materials Corp (3691)-エネルギー分野:企業M&A・提携分析
    Summary Gigasolar Materials Corp (Giga Solar), formerly Gigastorage optoelectronic materials is a solar products manufacturing company that manufactures and markets solar conductive pastes. The company’s products include solar cell backside aluminium paste, solar cell front side silver paste, and so …
  • Energy Transfer LP:企業の戦略・SWOT・財務情報
    Energy Transfer LP - Strategy, SWOT and Corporate Finance Report Summary Energy Transfer LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Tanita Corp:企業の戦略的SWOT分析
    Tanita Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Aperam SA:企業の戦略・SWOT・財務情報
    Aperam SA - Strategy, SWOT and Corporate Finance Report Summary Aperam SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Qiagen NV (QIA)-製薬・医療分野:企業M&A・提携分析
    Summary Qiagen NV (Qiagen) is a provider of molecular testing solutions. Its solutions include sample and assay technologies, bioinformatics and automation systems. Qiagen’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue. The company’s produc …
  • APR Applied Pharma Research SA-医療機器分野:企業M&A・提携分析
    Summary APR Applied Pharma Research SA (APR) is a healthcare company which focuses on the development and licenses of healthcare products for rare therapeutic areas. The company offers consumer health products, prescription healthcare products and therapeutic products. APR’s product pipeline portfol …
  • Buy It Direct Ltd:企業の戦略的SWOT分析
    Buy It Direct Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Anhui Water Resources Development Co Ltd (600502):企業の財務・戦略的SWOT分析
    Summary Anhui Water Resources Development Co Ltd (Anhui Water) is an investment holding company. The company operates in the business of construction, real estate development, and hydropower investment construction and operation. It operates as a general contractor of water conservancy projects, hou …
  • NV Energy Inc:電力:M&Aディール及び事業提携情報
    Summary NV Energy Inc (NVE) is an energy holding company, which provides a wide range of services through its principal subsidiaries, Nevada Power Co and Sierra Pacific Power Co. NVE delivers electricity to residential, commercial and industrial customers. It also sells electricity and natural gas t …
  • Damodar Valley Corp:電力:M&Aディール及び事業提携情報
    Summary Damodar Valley Corp (DVC) is a government owned multi-purpose river valley project. It generates, transmits, and supplies electricity; mines for and produces coal; manages water and conserves soil; and provides consultancy services. The company produces energy using thermal and hydro sources …
  • Cabot Corp (CBT):企業の財務・戦略的SWOT分析
    Cabot Corp (CBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • PDL BioPharma Inc (PDLI):医療機器:M&Aディール及び事業提携情報
    Summary PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions …
  • Balfour Beatty plc:企業の戦略・SWOT・財務分析
    Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report Summary Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • SCB Life Assurance Public Company Limited:戦略・SWOT・企業財務分析
    SCB Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary SCB Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆